Abstract
Angiotensin II (Ang II) has been shown to induce receptor activator of nuclear factor-κB ligand (RANKL) expression in osteoblasts associated with its effect on reactive oxygen species (ROS) production. The objective of the present study was to investigate the potential pathways by which Ang II induces RANKL expression and the role of ROS in Ang II-induced RANKL expression in mouse osteoblastic MC3T3-E1 cells. Treatment with Ang IIinduced RANKL expression in a dose- and time-dependent manner in osteoblasts, which was attenuated by pre-treatment with an AT1 receptor antagonist (olmesartan), ROS scavenger (N-acetylcysteine, NAC), or the ERK inhibitor (U0126), but not with AT2R antagonist (PD123319). Furthermore, Ang II enhanced AT1R and NAD(P)H oxidase (NOX) p22(phox) and p67(phox) expression and activity in osteoblasts. In addition, Ang II promoted ROS production, which was mitigated by pre-treatment with olmesartan or a NOX inhibitor (diphenyleneiodonium, DPI), but not with PD1123319 or U0126, in osteoblasts. Moreover, Ang II enhanced the ERK1/2 phosphorylation, which was abrogated by pre-treatment with olmesartan, NAC, DPI, or U0126 in osteoblasts. These results suggest that Ang II, through its AT1R, enhanced NOX activity and ROS production, and activated the ERK pathway to up-regulate RANKL expression in osteoblasts in vitro.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.